Related Experiment Video
Updated: Aug 7, 2026

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
Published on: May 11, 2020
Rabies virus glycoprotein as a carrier for anthrax protective antigen
Mary Ellen Smith1, Martin Koser, Sa Xiao
1Department of Microbiology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Abstract:
Live viral vectors expressing foreign antigens have shown great promise as vaccines against viral diseases. However, safety concerns remain a major problem regarding the use of even highly attenuated viral vectors. Using the rabies virus (RV) envelope protein as a carrier molecule, we show here that inactivated RV particles can be utilized to present Bacillus anthracis protective antigen (PA) domain-4 in the viral membrane. In addition to the RV glycoprotein (G) transmembrane and cytoplasmic domains, a portion of the RV G ectodomain was required to express the chimeric RV G anthrax PA on the cell surface. The novel antigen was also efficiently incorporated into RV virions. Mice immunized with the inactivated recombinant RV virions exhibited seroconversion against both RV G and anthrax PA, and a second inoculation greatly increased these responses. These data demonstrate that a viral envelope protein can carry a bacterial protein and that a viral carrier can display whole polypeptides compared to the limited epitope presentation of previous viral systems.
Related Concept Videos
Rabies
Inhalation Anthrax
Arboviral Encephalitis

